Parkinson Frontiers: focus on GBA1

The third edition of PD Frontiers focuses on Parkinson’s disease associated with GBA1 gene mutations-one of the most dynamic and promising areas in modern neurology.

The decision to dedicate the course to GBA1-related Parkinson’s disease reflects thestrategic importance of this subgroup. Variants of the GBA1 gene represent the most common genetic risk factor for Parkinson’s disease, found in a significant proportion of patients (5-15%, reaching up to 25% in specific cohorts).

Beyond its epidemiological relevance, this form stands out for its unique clinical and prognostic characteristics, which call for a dedicated diagnostic and therapeutic approach.

Recent evidence on pathogenic mechanisms-including lysosomal dysfunction, α-synuclein accumulation, oxidative stress, and mitochondrial deficits-has opened new therapeutic avenues that are now the focus of numerous advanced-stage clinical trials.

The scientific value of the course is ensured by the participation of leading national and international experts in genetics, neurobiology, and innovative therapies for GBA1-related Parkinson’s disease. Featuring both national and international lecturers, the seminar and the course offer participants a unique opportunity for up-to-date learning, critical discussion, and sharing of the latest scientific evidence.

This highly stimulating environment promotes dialogue among experts from complementary disciplines, helping to build a truly global scientific community dedicated to advancing knowledge and improving care for GBA1-related Parkinson’s disease.